medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 3

<< Back Next >>

Ann Hepatol 2006; 5 (3)

Intrahepatic cholestasis of pregnancy: A past and present riddle

Arrese M, Reyes H

Language: English
References: 44
Page: 202-205
PDF size: 78.08 Kb.


Text Extraction

Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy- specific disorders that occurs mainly in the third trimester of pregnancy and is characterized by pruritus and elevated bile acid levels. ICP is regarded as a benign disease with no meaningful consequences to the mother but associated to an increased perinatal risk with increased rates of fetal morbidity and mortality. The pathogenesis of disease is unknown but likely involves a genetic hypersensitivity to estrogen or estrogen metabolites. Mutations or polymorphisms of some hepatobiliary transport proteins may contribute to disease pathogenesis or severity. Treatment is focused on a) reducing symptoms in the mother and b) to provide an adequate obstetric management in order to prevent fetal distress. Currently, only Ursodeoxycholic acid treatment has been proven to be useful and should be considered mainly in patients with severe pruritus or complications in previous pregnancies.


REFERENCES

  1. Reyes H. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. J Gastroenterol Hepatol 1997; 12: 211-216.

  2. Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterol Clin North Am 1992; 21: 905-921.

  3. Reyes H. The enigma of intrahepatic cholestasis of pregnancy: lessons from Chile. Hepatology 1982; 2: 87-96.

  4. Rioseco AJ, Ivankovic MB, Manzur A, Hamed F, Kato SR, Parer JT, Germain AM. Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome. Am J Obstet Gynecol 1994; 170: 890-895.

  5. Sentilhes L, Verspyck E, Pia P, Marpeau L. Fetal death in a patient with intrahepatic cholestasis of pregnancy. Obstet Gynecol 2006; 107: 458-460.

  6. Germain AM, Carvajal JA, Glasinovic JC, Kato CS, Williamson C. Intrahepatic cholestasis of pregnancy: an intriguing pregnancy-specific disorder. J Soc Gynecol Investig 2002; 9: 10-14.

  7. Lammert F, Marschall HU, Glantz A, Matern S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol 2000; 33: 1012-1021.

  8. Reyes H, Gonzalez MC, Ribalta J, Aburto H, Matus C, Schramm G, Katz R, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88: 487-493.

  9. Reyes H, Baez ME, Gonzalez MC, Hernandez I, Palma J, Ribalta J, Sandoval L, et al. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile. J Hepatol 2000; 32: 542-549.

  10. Nichols AA. Cholestasis of pregnancy: a review of the evidence. J Perinat Neonatal Nurs 2005; 19: 217-225.

  11. Arrese MPM, Solis N, Accatino L. Pregnancy and hepatic transport: implications for the pathogenesis of intrahepatic cholestasis of pregnancy. In: U. Leuschner P.A. Berg JHe, ed. Bile Acids and Pregnancy. Dordrecht/Boston/Londres: Kluwer Academic Publishers, Lancaster, 2002: 39-45.

  12. Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin Liver Dis 1993; 13: 289-301.

  13. Gonzalez MC, Reyes H, Arrese M, Figueroa D, Lorca B, Andresen M, Segovia N, et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. J Hepatol 1989; 9: 84-90.

  14. Arrese M, Trauner M, Ananthanarayanan M, Pizarro M, Solis N, Accatino L, Soroka C, et al. Down-regulation of the Na+/taurocholate cotransporting polypeptide during pregnancy in the rat. J Hepatol 2003; 38: 148-155.

  15. Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol 2005; 4: 77-99.

  16. Meng LJ, Reyes H, Axelson M, Palma J, Hernandez I, Ribalta J, Sjovall J. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology 1997; 26: 1573-1579.

  17. Reyes H, Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000; 32: 94-106.

  18. Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJ. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol 2006; 44: 1150-1157.

  19. Reyes H, Ribalta J, Gonzalez MC, Segovia N, Oberhauser E. Sulfobromophthalein clearance tests before and after ethinyl estradiol administration, in women and men with familial history of intrahepatic cholestasis of pregnancy. Gastroenterology 1981; 81: 226-231.

  20. Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006; 130: 908-925.

  21. Painter JN, Savander M, Ropponen A, Nupponen N, Riikonen S, Ylikorkala O, Lehesjoki AE, et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 2005; 13: 435-439.

  22. Lang T, Haberl M, Jung D, Drescher A, Schlagenhaufer R, Keil A, Mornhinweg E, et al. Genetic Variability, Haplotype Structures, and Ethnic Diversity of Hepatic Transporters MDR3 (ABCB4) and Bile Salt Export Pump (ABCB11). Drug Metab Dispos 2006; 34: 1582-1599.

  23. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, Zimmermann R, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102.

  24. Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 2006; 131: 624-629.

  25. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 2001; 21: 551-562.

  26. Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003; 124: 1037-1042.

  27. Arrese M, Accatino L. Is intrahepatic cholestasis of pregnancy an MDR3-related disease? Gastroenterology 2003; 125: 1922-1923; author reply 1923-1924.

  28. Reyes H, Ribalta J, Hernandez I, Arrese M, Pak N, Wells M, Kirsch RE. Is dietary erucic acid hepatotoxic in pregnancy? An experimental study in rats and hamsters. Hepatology 1995; 21: 1373-1379.

  29. Germain AM, Kato S, Carvajal JA, Valenzuela GJ, Valdes GL, Glasinovic JC. Bile acids increase response and expression of human myometrial oxytocin receptor. Am J Obstet Gynecol 2003; 189: 577-582.

  30. Perez MJ, Macias RI, Duran C, Monte MJ, Gonzalez-Buitrago JM, Marin JJ. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol 2005; 43: 324-332.

  31. Williamson C, Gorelik J, Eaton BM, Lab M, de Swiet M, Korchev Y. The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clin Sci (Lond) 2001; 100: 363-369.

  32. Macias RI, Pascual MJ, Bravo A, Alcalde MP, Larena MG, St-Pierre MV, Serrano MA, et al. Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem. Hepatology 2000; 31: 975-983.

  33. Arrese M, Trauner M, Ananthanarayanan M, Boyer JL, Suchy FJ. Maternal cholestasis does not affect the ontogenic pattern of expression of the Na+/taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. Hepatology 1998; 28: 789-795.

  34. Serrano MA, Monte MJ, Martinez-Diez MC, Marin JJ. Effect of maternal cholestasis on the kinetics of bile acid transport across the canalicular membrane of infant rat livers. Int J Exp Pathol 1997; 78: 383-390.

  35. Riely CA, Bacq Y. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 2004; 8: 167-176.

  36. Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1995; 102: 169-170.

  37. Zapata R, Sandoval L, Palma J, Hernandez I, Ribalta J, Reyes H, Sedano M, et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int 2005; 25: 548-554.

  38. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-328.

  39. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42: 1399-1405.

  40. Heikkinen J, Maentausta O, Ylostalo P, Janne O. Serum bile acid levels in intrahepatic cholestasis of pregnancy during treatment with phenobarbital or cholestyramine. Eur J Obstet Gynecol Reprod Biol 1982; 14: 153-162.

  41. Ribalta J, Reyes H, Gonzalez MC, Iglesias J, Arrese M, Poniachik J, Molina C, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, doubleblind, placebo-controlled study with negative results. Hepatology 1991; 13: 1084-1089.

  42. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40: 467-474.

  43. Sentilhes L, Verspyck E, Roman H, Marpeau L. Intrahepatic cholestasis of pregnancy and bile acid levels. Hepatology 2005; 42: 737-738; author reply 738.

  44. Popper H. Cholestasis: the future of a past and present riddle. Hepatology 1981; 1: 187-191.




2020     |     www.medigraphic.com